RECOVERY & TISSUE REPAIR / COMPARE
Three Peptides, Side by Side
Where GHK-Cu, TB-500, and BPC-157 converge, where they diverge, and how far the evidence behind each actually reaches.
The short version
This page lines up GHK-Cu, TB-500, and BPC-157 on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is simple. All three are studied for recovery and tissue repair, but from different angles and at very different stages of human evidence: GHK-Cu has the most human (mostly topical) data, BPC-157 has the deepest animal record with three tiny human pilots, and TB-500's evidence largely belongs to a much larger parent protein. None is an approved medicine, and none is presented here with a human dose.
The comparison matrix
| Dimension | GHK-Cu | TB-500 | BPC-157 |
|---|---|---|---|
| Peptide class | Copper-binding tripeptide / copper tripeptide-1 (3 aa) | Synthetic actin-binding fragment of thymosin beta-4 (7 aa) | Stable gastric pentadecapeptide (15 aa) |
| Most-studied in | Skin regeneration and matrix synthesis | Actin biology; cell migration and angiogenesis | Tendon, gut, muscle, and nerve repair |
| Evidence base (model) | In vitro + small human topical trials [4][1] | Mostly full-length Tβ4 (animal + 1 human Phase 1) [8][11] | Mostly rat; 3 small human pilots [14] |
| Administration studied | Topical; ex vivo skin penetration [1][5] | IV (full-length Tβ4), IP in animals [9][11] | IM, intragastric, drinking water, IV pilot [13][17] |
| Regulatory / WADA status | Cosmetic ingredient (topical); systemic unapproved | Not approved; WADA-prohibited | Not approved; WADA S0 prohibited |
| Key caution | Poor skin permeability; single-lab origin of gene-expression claims [1][2] | Fragment vs full-protein identity gap [8] | Single-lab, preclinical-heavy record [14] |
Peptide class
The three cover a size range. GHK-Cu is the smallest at three amino acids — a copper-carrying tripeptide whose sequence is embedded in type I collagen [4]. TB-500 is seven amino acids, a synthetic fragment carrying the actin-binding motif of the much larger thymosin beta-4 protein. BPC-157 is the largest at fifteen amino acids, a stable gastric pentadecapeptide drawn from a cytoprotective gastric protein [17]. Different sizes, different origins, different mechanisms.
Most-studied in
Each peptide has a research home territory. GHK-Cu is overwhelmingly a skin-and-matrix story — collagen synthesis, elastin, and the dermal environment — with the clearest biological rationale rooted in type I collagen biology [4][6]. TB-500's research centers on actin regulation and the cell migration and angiogenesis that follow from it, across dermal, corneal, heart, and CNS models [10]. BPC-157's animal record is the broadest, spanning tendon, gut, muscle, and nerve repair, with angiogenesis as the unifying mechanism [16][17].
Evidence base (model)
This is where the three genuinely separate. GHK-Cu has the most human data, but it is mostly topical and small-scale, plus one 45-patient combination hair-loss trial [3][4]. BPC-157 has a deep, decades-long animal record and three small uncontrolled human pilots — a recent 2025 review describes only three pilot studies with no rigorous large-scale trials [14]. TB-500 is the trickiest: its strongest human data — a Phase 1 intravenous safety study in 40 volunteers — used full-length thymosin beta-4, not the marketed fragment, and no completed clinical trials of the fragment itself exist [8][11].
Administration studied
Routes track the research questions. GHK-Cu is studied topically, with ex vivo skin-penetration measurements quantifying copper passage through skin layers and dermal depot formation [1][5]. TB-500/Tβ4 work used intravenous dosing in the human Phase 1 study and intraperitoneal dosing in rat models [9][11]. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot [13][17].
Regulatory and WADA status
None of the three is an FDA- or EMA-approved medicine for systemic use. BPC-157 and TB-500 are both prohibited in sport by WADA — BPC-157 under the S0 non-approved-substances category and TB-500 under prohibited peptide/growth-factor categories [8]. GHK-Cu is unusual in this respect: topical copper tripeptide-1 is a legal, widely sold cosmetic ingredient in the US, EU, and UK, while injectable or systemic GHK-Cu is unapproved and research-only [1].
Key caution
Each carries a defining caveat. For GHK-Cu it is the poor skin permeability that limits how much actually reaches the dermis, plus the single-lab origin of many gene-expression claims that limits independent replication [1][2]. For TB-500 it is the identity gap — the marketed seven-amino-acid fragment is not the molecule behind most of the efficacy data, and the parent protein has a theoretical tumor-angiogenesis signal [8][10]. For BPC-157 it is that the broad, internally consistent signal lives mostly in one group's rodent experiments, with only three tiny human pilots to date [14]. Reading them together, the lesson is consistent: mechanistically interesting, often preclinical, evidence in need of rigorous human trials.